SQZ Biotechnologies is a clinical-stage biotechnology company focused on developing cell-based therapies for a range of diseases, including cancer and autoimmune disorders. The company’s proprietary Cell Squeeze® platform enables the delivery of therapeutic cargo directly into the cytosol of cells by mechanically creating transient pores in the cell membrane. This approach is designed to enhance antigen presentation in immune cells, offering a novel route for generating potent and targeted immunotherapies.
Building on its platform, SQZ Biotechnologies has established a pipeline of product candidates that leverage both autologous and allogeneic cells. Lead programs include cancer vaccine candidates that aim to program a patient’s own antigen-presenting cells to recognize and attack tumors, as well as regulatory T-cell therapies for autoimmune indications. The platform’s modularity allows for rapid prototyping of multiple therapeutic modalities, from protein delivery to gene editing applications, positioning SQZ to address unmet medical needs across therapeutic areas.
Founded in 2014 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies went public in 2021 and maintains research and development facilities in the greater Boston area. Since its inception, the company has partnered with academic institutions and biopharmaceutical leaders to validate the Cell Squeeze technology in preclinical and early clinical settings. In addition to its U.S. base, SQZ collaborates with international research centers to accelerate global development and expand its clinical footprint.
The company’s leadership team brings together scientific pioneers and seasoned industry executives. Co-founder and Chief Scientific Officer Armon Sharei has overseen platform development since SQZ’s origin, while a management team with prior experience at leading biotechnology and pharmaceutical firms drives clinical and commercial strategy. Guided by a board of directors with deep expertise in cell therapy and immunology, SQZ Biotechnologies aims to translate its novel delivery technology into first-in-class treatments for patients worldwide.
AI Generated. May Contain Errors.
